Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome - PubMed (original) (raw)
Review
Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome
A McLean-Tooke et al. Scand J Immunol. 2007 Jul.
Free article
Abstract
22q11.2 deletion syndrome is the commonest chromosome deletion syndrome. 22q11.2 deletion may result in variable clinical phenotypes which may differ even between patients with identical deletions. Abnormal pharyngeal arch development results in defects in the development of the parathyroid glands, thymus and conotruncal region of the heart. Defective thymic development is associated with impaired immune function. 'Complete' DiGeorge syndrome with total absence of the thymus and a severe T-cell immunodeficiency accounts for <0.5% of patients. The majority of patients with 22q11.2 deletion syndromes have 'partial' defects with impaired thymic development rather than complete absence with variable defects in T-cell numbers. Immunodeficiency in these patients is not solely due to T-cell deficiency and abnormalities of T-cell clonality or impairment of proliferative responses may play a role. Humoral deficiencies including defects in the B-cell compartment have also been identified in these patients. 22q11.2 deletion syndrome patients are at increased risk of a variety of autoimmune diseases. A number of immune defects may predispose to the development of autoimmunity in these patients including increased infection, impaired development of natural T-regulatory cells and impaired thymic central tolerance.
Similar articles
- Immunological aspects of 22q11.2 deletion syndrome.
Gennery AR. Gennery AR. Cell Mol Life Sci. 2012 Jan;69(1):17-27. doi: 10.1007/s00018-011-0842-z. Epub 2011 Oct 9. Cell Mol Life Sci. 2012. PMID: 21984609 Free PMC article. Review. - Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes.
Sullivan KE, Jawad AF, Randall P, Driscoll DA, Emanuel BS, McDonald-McGinn DM, Zackai EH. Sullivan KE, et al. Clin Immunol Immunopathol. 1998 Feb;86(2):141-6. doi: 10.1006/clin.1997.4463. Clin Immunol Immunopathol. 1998. PMID: 9473376 - An Fgf8 mouse mutant phenocopies human 22q11 deletion syndrome.
Frank DU, Fotheringham LK, Brewer JA, Muglia LJ, Tristani-Firouzi M, Capecchi MR, Moon AM. Frank DU, et al. Development. 2002 Oct;129(19):4591-603. doi: 10.1242/dev.129.19.4591. Development. 2002. PMID: 12223415 Free PMC article. - Immunologic defects in 22q11.2 deletion syndrome.
McLean-Tooke A, Barge D, Spickett GP, Gennery AR. McLean-Tooke A, et al. J Allergy Clin Immunol. 2008 Aug;122(2):362-7, 367.e1-4. doi: 10.1016/j.jaci.2008.03.033. Epub 2008 May 16. J Allergy Clin Immunol. 2008. PMID: 18485468 - DiGeorge syndrome/chromosome 22q11.2 deletion syndrome.
Sullivan KE. Sullivan KE. Curr Allergy Asthma Rep. 2001 Sep;1(5):438-44. doi: 10.1007/s11882-001-0029-z. Curr Allergy Asthma Rep. 2001. PMID: 11892070 Review.
Cited by
- Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors.
Cillo F, Coppola E, Habetswallner F, Cecere F, Pignata L, Toriello E, De Rosa A, Grilli L, Ammendola A, Salerno P, Romano R, Cirillo E, Merla G, Riccio A, Pignata C, Giardino G. Cillo F, et al. Genes (Basel). 2024 Feb 29;15(3):321. doi: 10.3390/genes15030321. Genes (Basel). 2024. PMID: 38540380 Free PMC article. Review. - Distinct Immunophenotypic Features in Patients Affected by 22q11.2 Deletion Syndrome with Immune Dysregulation and Infectious Phenotype.
Costagliola G, Legitimo A, Bertini V, Alberio AMQ, Valetto A, Consolini R. Costagliola G, et al. J Clin Med. 2023 Dec 8;12(24):7579. doi: 10.3390/jcm12247579. J Clin Med. 2023. PMID: 38137647 Free PMC article. - Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up.
Sarli WM, Ricci S, Lodi L, Cavone F, Pacillo L, Giancotta C, Ubertini G, Baroncelli G, Cancrini C, Azzari C, Stagi S. Sarli WM, et al. Front Endocrinol (Lausanne). 2023 Aug 10;14:1209577. doi: 10.3389/fendo.2023.1209577. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37635986 Free PMC article. - ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1.
Takahashi S, Takada I, Hashimoto K, Yokoyama A, Nakagawa T, Makishima M, Kume H. Takahashi S, et al. Sci Rep. 2023 Jul 31;13(1):12355. doi: 10.1038/s41598-023-39626-0. Sci Rep. 2023. PMID: 37524814 Free PMC article. - Neuroinflammation and Oxidative Stress in Individuals Affected by DiGeorge Syndrome.
Menghi M, Micangeli G, Tarani F, Putotto C, Pirro F, Mariani A, Petrella C, Pulvirenti F, Cinicola B, Colloridi F, Tarani L, Fiore M. Menghi M, et al. Int J Mol Sci. 2023 Feb 20;24(4):4242. doi: 10.3390/ijms24044242. Int J Mol Sci. 2023. PMID: 36835652 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical